Literature DB >> 27108193

The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations.

Daniela Frasca1, Alain Diaz2, Maria Romero2, Bonnie B Blomberg2.   

Abstract

The success of a vaccine in inducing a protective antibody response depends on the longevity of both long-lived plasma cells (PC) and memory B cells. We have previously shown that the in vivo antibody response to a new influenza vaccine, the ex vivo plasmablast response, the in vitro B cell function, measured by AID (activation-induced cytidine deaminase), and the transcription factor E47, are significantly associated and decreased in elderly individuals. We hypothesized that because AID is decreased in the elderly, the ability to generate memory B cells would also be decreased, but our findings here show that memory B cells are maintained in the elderly probably due to further amplification in response to repeated vaccination. We recruited young and elderly individuals immunized in at least two consecutive influenza vaccine seasons in which the influenza A viral strains H1N1 and H3N2 in the vaccine were the same as in the previous year. PBMC were cultured with CpG/IL2 to measure the frequency of IgG vaccine-specific memory B cells. Serum antibody response was measured by hemagglutination inhibition assay. Blood plasmablasts were measured by flow cytometry. Surprisingly, the frequencies of influenza vaccine-specific memory B cells and plasmablasts were similar in young and elderly individuals, but the fold-increase in serum titers after vaccination was lower in the elderly although most of the elderly were seroprotected. We then measured the transcription factor Blimp-1, considered the master regulator of PC differentiation, and found it significantly reduced in cultures of B cells from elderly versus young individuals, as well as E47/AID and IgG secretion. Taken together, these results suggest an impaired memory B cell to PC differentiation in the elderly.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aging; Antibody responses; Influenza vaccine; Memory B cells

Mesh:

Substances:

Year:  2016        PMID: 27108193      PMCID: PMC4876633          DOI: 10.1016/j.vaccine.2016.04.023

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  39 in total

1.  Immune response to influenza vaccination in a large healthy elderly population.

Authors:  E Bernstein; D Kaye; E Abrutyn; P Gross; M Dorfman; D M Murasko
Journal:  Vaccine       Date:  1999-01       Impact factor: 3.641

2.  Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly.

Authors:  Donna M Murasko; Erica D Bernstein; Elizabeth M Gardner; Peter Gross; Gary Munk; Sandra Dran; Elias Abrutyn
Journal:  Exp Gerontol       Date:  2002 Jan-Mar       Impact factor: 4.032

3.  Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Mitch Phillips; Nicholas V Mendez; Ana Marie Landin; Bonnie B Blomberg
Journal:  Int Immunol       Date:  2012-01-25       Impact factor: 4.823

4.  Duration of humoral immunity to common viral and vaccine antigens.

Authors:  Ian J Amanna; Nichole E Carlson; Mark K Slifka
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

5.  Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children.

Authors:  Nitin Verma; Milena Dimitrova; Donald M Carter; Corey J Crevar; Ted M Ross; Hana Golding; Surender Khurana
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

6.  High TNF-α levels in resting B cells negatively correlate with their response.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Ana Marie Landin; Bonnie B Blomberg
Journal:  Exp Gerontol       Date:  2014-01-15       Impact factor: 4.032

7.  Plasma cell numbers decrease in bone marrow of old patients.

Authors:  Theresa Pritz; Julian Lair; Michael Ban; Michael Keller; Birgit Weinberger; Martin Krismer; Beatrix Grubeck-Loebenstein
Journal:  Eur J Immunol       Date:  2014-12-23       Impact factor: 5.532

8.  AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.

Authors:  Janet E McElhaney; Jiri Beran; Jeanne-Marie Devaster; Meral Esen; Odile Launay; Geert Leroux-Roels; Guillermo M Ruiz-Palacios; Gerrit A van Essen; Adrian Caplanusi; Carine Claeys; Christelle Durand; Xavier Duval; Mohamed El Idrissi; Ann R Falsey; Gregory Feldman; Sharon E Frey; Florence Galtier; Shinn-Jang Hwang; Bruce L Innis; Martina Kovac; Peter Kremsner; Shelly McNeil; Andrzej Nowakowski; Jan Hendrik Richardus; Andrew Trofa; Lidia Oostvogels
Journal:  Lancet Infect Dis       Date:  2013-03-19       Impact factor: 25.071

9.  Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011-2012 influenza vaccine season.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Nicholas V Mendez; Ana Marie Landin; Bonnie B Blomberg
Journal:  Immun Ageing       Date:  2013-04-22       Impact factor: 6.400

10.  Influence of prior influenza vaccination on antibody and B-cell responses.

Authors:  Sanae Sasaki; Xiao-Song He; Tyson H Holmes; Cornelia L Dekker; George W Kemble; Ann M Arvin; Harry B Greenberg
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

View more
  42 in total

Review 1.  [Oncoimmunology in old age].

Authors:  M C Wigand; S Jeske; J Hahn; J Doescher; S Laban; T K Hoffmann; P J Schuler
Journal:  HNO       Date:  2020-03       Impact factor: 1.284

2.  Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage.

Authors:  Shahzma Merani; George A Kuchel; Alison Kleppinger; Janet E McElhaney
Journal:  Exp Gerontol       Date:  2017-09-27       Impact factor: 4.032

Review 3.  Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19.

Authors:  Judy Chen; William J Kelley; Daniel R Goldstein
Journal:  J Immunol       Date:  2020-06-03       Impact factor: 5.422

4.  B Cell-Specific Biomarkers for Optimal Antibody Responses to Influenza Vaccination and Molecular Pathways That Reduce B Cell Function with Aging.

Authors:  Daniela Frasca; Bonnie B Blomberg
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

5.  Preexisting subtype immunodominance shapes memory B cell recall response to influenza vaccination.

Authors:  Rodrigo B Abreu; Greg A Kirchenbaum; Emily F Clutter; Giuseppe A Sautto; Ted M Ross
Journal:  JCI Insight       Date:  2020-01-16

6.  Induction of IL21 in Peripheral T Follicular Helper Cells Is an Indicator of Influenza Vaccine Response in a Previously Vaccinated HIV-Infected Pediatric Cohort.

Authors:  Lesley R de Armas; Nicola Cotugno; Suresh Pallikkuth; Li Pan; Stefano Rinaldi; M Celeste Sanchez; Louis Gonzalez; Alberto Cagigi; Paolo Rossi; Paolo Palma; Savita Pahwa
Journal:  J Immunol       Date:  2017-01-27       Impact factor: 5.422

Review 7.  Host Factors Impact Vaccine Efficacy: Implications for Seasonal and Universal Influenza Vaccine Programs.

Authors:  Santosh Dhakal; Sabra L Klein
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

Review 8.  Aging, cancer, and antitumor immunity.

Authors:  Hideki Ikeda; Yosuke Togashi
Journal:  Int J Clin Oncol       Date:  2021-03-30       Impact factor: 3.402

Review 9.  Age-related factors that affect B cell responses to vaccination in mice and humans.

Authors:  Daniela Frasca; Bonnie B Blomberg; Denisse Garcia; Spencer R Keilich; Laura Haynes
Journal:  Immunol Rev       Date:  2020-06-02       Impact factor: 12.988

Review 10.  Understanding immunosenescence and its impact on vaccination of older adults.

Authors:  Jessica C Allen; Franklin R Toapanta; Wilbur Chen; Sharon M Tennant
Journal:  Vaccine       Date:  2020-11-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.